While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints. First Published Jan 29, 2025, 1:04 AM IST | …

Key Takeaways Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease. The drug, known as EFX, helped reverse cirrhosis of the liver in patients with metabolic …

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and …

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation …

MANILA, Philippines — Trade Secretary Cristina Roque reported on Saturday that the British-Swedish pharmaceutical AstraZeneca expressed interest in conducting most of its clinical trials in the Philippines. Reporting on her activities at the annual World …

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk rose as much as 13 per cent on Friday on hopes that positive trial results for a new weight loss drug give …

Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese and overweight patients taking 20 milligrams of the …

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug. The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people …

Novo Nordisk said the trial showed that its once-weekly amycretin obesity drug resulted in an average weight reduction of 22% in obese and overweight patients after 36 weeks, compared to a weight gain of 2.0% among patients treated with placebo. "We …

First Published Jan 24, 2025, 6:59 PM IST | Last Updated Jan 24, 2025, 6:59 PM IST Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage trial of amycretin, a new weight-loss drug …